Healthcare · Biotechnology
Price
$1.61
Market Cap
$17.4M
Employees
5
Beta
1.45
Avg Volume
86,558
CEO
Juan F. Vera
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.
Runs with full report
Price Overview
Last updated: Jul 8, 2026 7:20pm (just now)
Current data · timestamped when a report runs
$1.61
Change · Jul 8
-0.07 (-4.17%)
Day Range
$1.59 – $1.70
52-Week Range
$0.81 – $4.07
50-Day MA
$1.43
200-Day MA
$1.37
Volume
132,037.00
Share Structure
Outstanding
10,797,737.00
Float
10,386,322.00
Free Float
96.2%
High free float
— 96.2% of shares trade freely, ~3.8% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-2.04
Stock Price: $1.61
EPS (Diluted): -0.79
EPS (Diluted): -0.79
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
1.36
Stock Price: $1.61
Total Equity: $16.80M
Shares: 15,310,000
Total Equity: $16.80M
Shares: 15,310,000
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-0.23
Market Cap: $17.38M
Total Debt: $0.00
Cash: $16.07M
EBITDA: -$12.44M
Total Debt: $0.00
Cash: $16.07M
EBITDA: -$12.44M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$6.7M
Market Cap: $17.38M
Total Debt: $0.00
Cash: $16.07M
Total Debt: $0.00
Cash: $16.07M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $1.61
Revenue: $0.00
Shares: 15,310,000
Revenue: $0.00
Shares: 15,310,000
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: $0.00
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$12.89M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$12.16M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-73.3%
Net Income: -$12.16M
Total Equity: $16.80M
Total Equity: $16.80M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-89.4%
Operating Income: -$12.89M
Tax Rate: 0.1%
Equity: $16.80M
Total Debt: $0.00
Cash: $16.07M
Tax Rate: 0.1%
Equity: $16.80M
Total Debt: $0.00
Cash: $16.07M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
8.39
Current Assets: $19.07M
Current Liabilities: $2.27M
Current Liabilities: $2.27M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $16.80M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $16.80M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 15,310,000
Shares: 15,310,000
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$1.10
Total Equity: $16.80M
Shares: 15,310,000
Shares: 15,310,000
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-0.78
Operating CF: -$12.01M
CapEx: $0.00
Shares: 15,310,000
CapEx: $0.00
Shares: 15,310,000
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $1.61
Stock Price: $1.61
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$12.16M
Net Income: -$12.16M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares MRKR against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jul 7, 2026 6:18pm (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $1.2M | $3.5M | $3.3M | $6.6M | $0 |
| Cost of Revenue | $3.2M | $12.0M | $10.4M | $13.5M | $0 |
| Gross Profit | -$1.9M | -$8.5M | -$7.1M | -$6.9M | $0 |
| Operating Expenses | $37.6M | $11.3M | $7.5M | $4.2M | $12.9M |
| Operating Income | -$39.5M | -$19.8M | -$14.6M | -$11.1M | -$12.9M |
| Net Income | -$41.9M | -$29.9M | -$8.2M | -$10.7M | -$12.2M |
| EBITDA | -$38.7M | -$17.0M | -$11.3M | -$10.7M | -$12.4M |
| EPS | $-5.47 | $-3.58 | $-1.93 | $-1.19 | $-0.79 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jul 7, 2026 6:18pm (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $42.4M | $11.8M | $15.1M | $19.2M | $16.1M |
| Total Current Assets | $46.0M | $16.6M | $17.1M | $22.0M | $19.1M |
| Total Assets | $68.1M | $34.4M | $17.1M | $22.0M | $19.1M |
| Current Liabilities | $12.9M | $7.8M | $3.1M | $3.5M | $2.3M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $24.1M | $14.8M | $3.1M | $3.5M | $2.3M |
| Total Equity | $44.0M | $19.6M | $14.1M | $18.6M | $16.8M |
| Retained Earnings | -$398.1M | -$428.0M | -$436.3M | -$447.0M | -$459.2M |
Cash Flow (Annual)
Last updated: Jul 7, 2026 6:18pm (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$27.3M | -$27.0M | -$16.4M | -$10.9M | -$12.0M |
| Capital Expenditure | -$3.1M | $3 | $1 | $4 | $0 |
| Free Cash Flow | -$30.4M | -$27.0M | -$16.4M | -$10.9M | -$12.0M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $22.1M | -$31.7M | $3.3M | $4.1M | -$2.1M |
Analyst Estimates (Annual)
Last updated: Jul 8, 2026 7:20pm (just now)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$20.1M $6.5M – $33.7M
|
$83.9M $83.9M – $83.9M
|
$163.6M $50.9M – $265.1M
|
$316.9M $98.6M – $513.5M
|
| EBITDA |
-$12.1M -$20.2M – -$3.9M
|
-$50.3M -$50.3M – -$50.3M
|
-$98.2M -$159.1M – -$30.5M
|
-$190.1M -$308.1M – -$59.2M
|
| Net Income |
-$15.5M -$16.5M – -$14.4M
|
$14.8M -$15.6M – $22.0M
|
$30.1M $3.1M – $54.4M
|
$82.8M $8.6M – $149.6M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jul 7, 2026 6:18pm (1d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +183.0% | -5.8% | +99.1% | -100.0% |
| Gross Profit Growth | -340.1% | +16.0% | +3.2% | +100.0% |
| Operating Income Growth | +49.9% | +26.3% | +23.7% | -15.9% |
| Net Income Growth | +28.5% | +72.5% | -30.3% | -13.3% |
| EBITDA Growth | +56.1% | +33.8% | +5.1% | -16.4% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2025-11-17 | Knobil Katharine | A-Award | 137,330.00 | $0.95 | $131,123 |
| 2025-11-17 | Knobil Katharine | A-Award | 84,411.00 | $0.95 | $80,596 |
| 2025-11-17 | Eansor Norman David | A-Award | 137,330.00 | $0.95 | $131,123 |
| 2025-11-17 | Eansor Norman David | A-Award | 84,411.00 | $0.95 | $80,596 |
| 2025-11-17 | ELMS STEVE | A-Award | 137,330.00 | $0.95 | $131,123 |
| 2025-11-17 | ELMS STEVE | A-Award | 84,411.00 | $0.95 | $80,596 |
| 2025-10-31 | Corzo Kathryn Penkus | A-Award | 147,611.00 | $0.99 | $145,795 |
| 2025-10-31 | Vera Juan | A-Award | 250,000.00 | $0.99 | $246,925 |
| 2025-10-31 | Corzo Kathryn Penkus | 0.00 | $0.00 | $0 | |
| 2025-02-12 | ELMS STEVE | A-Award | 30,000.00 | $1.59 | $47,700 |
| 2025-02-12 | Knobil Katharine | A-Award | 30,000.00 | $1.59 | $47,700 |
| 2025-02-12 | Eansor Norman David | A-Award | 30,000.00 | $1.59 | $47,700 |
| 2025-02-12 | Vera Juan | A-Award | 50,000.00 | $1.59 | $79,500 |
| 2024-12-23 | ELMS STEVE | P-Purchase | 11,085.00 | $3.20 | $35,472 |
| 2024-12-23 | New Enterprise Associates 16, L.P. | P-Purchase | 554,250.00 | $3.20 | $1.8M |
| 2023-06-30 | Lurier Eliot M | 0.00 | $0.00 | $0 | |
| 2021-03-16 | Eansor Norman David | P-Purchase | 14,285.00 | $17.50 | $249,988 |
| 2023-06-06 | Eansor Norman David | A-Award | 8,000.00 | $1.72 | $13,760 |
| 2021-03-25 | Eansor Norman David | G-Gift | 7,142.00 | $0.00 | $0 |
| 2021-03-25 | Eansor Norman David | G-Gift | 14,285.00 | $0.00 | $0 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for MRKR — it's generated by the pipeline (
market-narrative step).
No community reviews yet for MRKR.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.392 · 5bda1781 · 2026-07-08 16:12:24